Zomedica Corp. (ZOM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZOM POWR Grades
- Growth is the dimension where ZOM ranks best; there it ranks ahead of 70.54% of US stocks.
- The strongest trend for ZOM is in Sentiment, which has been heading up over the past 47 days.
- ZOM's current lowest rank is in the Stability metric (where it is better than 1.71% of US stocks).
ZOM Stock Summary
- With a price/sales ratio of 79.66, Zomedica Corp has a higher such ratio than 97.25% of stocks in our set.
- ZOM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.6% of US stocks.
- As for revenue growth, note that ZOM's revenue has grown 13,761.63% over the past 12 months; that beats the revenue growth of 99.81% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Zomedica Corp, a group of peers worth examining would be EVOK, EBET, MICT, BLDE, and RIOT.
- Visit ZOM's SEC page to see the company's official filings. To visit the company's web site, go to www.zomedica.com.
ZOM Valuation Summary
- ZOM's EV/EBIT ratio is -19.6; this is 166.89% lower than that of the median Healthcare stock.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
- ZOM's price/sales ratio has moved NA NA over the prior 46 months.
Below are key valuation metrics over time for ZOM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ZOM | 2021-08-31 | 20836.7 | 2.3 | -34.9 | -19.6 |
| ZOM | 2021-08-30 | 20216.7 | 2.2 | -33.9 | -18.5 |
| ZOM | 2021-08-27 | 20640.0 | 2.2 | -34.6 | -19.2 |
| ZOM | 2021-08-26 | 22533.3 | 2.4 | -37.8 | -22.4 |
| ZOM | 2021-08-25 | 18940.0 | 2.1 | -31.7 | -16.4 |
| ZOM | 2021-08-24 | 16623.3 | 1.8 | -27.9 | -12.5 |
ZOM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ZOM has a Quality Grade of F, ranking ahead of 3.62% of graded US stocks.
- ZOM's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ZOM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | -0.393 | -5.936 |
| 2021-03-31 | 0 | 0.599 | -5.609 |
| 2020-12-31 | 0 | NA | -5.395 |
| 2020-09-30 | 0 | NA | -6.260 |
| 2020-06-30 | 0 | NA | -6.329 |
| 2020-03-31 | 0 | NA | -5.504 |
ZOM Stock Price Chart Interactive Chart >
ZOM Price/Volume Stats
| Current price | $0.21 | 52-week high | $0.81 |
| Prev. close | $0.22 | 52-week low | $0.18 |
| Day low | $0.21 | Volume | 23,201,000 |
| Day high | $0.22 | Avg. volume | 19,267,205 |
| 50-day MA | $0.24 | Dividend yield | N/A |
| 200-day MA | $0.35 | Market Cap | 203.62M |
Zomedica Corp. (ZOM) Company Bio
Zomedica Pharmaceuticals Corp. operates as a veterinary pharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of drugs, novel drug delivery systems, devices, and diagnostics for the health and wellness of companion animals, such as canine, feline, and equine. The company has a research collaboration agreement with Celsee Diagnostics, Inc. to test the feasibility of Celsee's liquid biopsy technology for veterinary application as a canine cancer diagnostics. Zomedica Pharmaceuticals Corp. was founded in 2015 and is based in Ann Arbor, Michigan.
Latest ZOM News From Around the Web
Below are the latest news stories about Zomedica Corp that investors may wish to consider to help them evaluate ZOM as an investment opportunity.
Dogs Win, Investors Lose With ZomedicaZomedica said last year that Truforma would revolutionize veterinary care with radio waves. |
It’s Going to Take a Lot to Get Zomedica Stock Out of the DoghouseZOM stockholders are likely to grow increasingly frustrated with management's misplaced optimism and the lack of Truforma sales. |
Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica?Zomedica Corp. |
Zomedica Corporation Reports 2021 Fourth Quarter & Full Year ResultsANN ARBOR, MI / ACCESSWIRE / March 1, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today reported consolidated financial results for the year ended December 31, 2021. |
Zomedica Announces Participation in the Q1 Virtual Investor SummitAnn Arbor, Michigan--(Newsfile Corp. - February 28, 2022) - Zomedica (AMEX: ZOM) today announced that Larry Heaton, CEO will be attending the Q1 Virtual Investor Summit. During the presentation, Zomedica’s Chief Executive Officer, Larry Heaton, will highlight the Company's recent integration of PulseVet, Inc., it's progress with the TRUFORMA product line, and the resulting transformational business strategy and partnerships, and the broader going-forward corporate vision. The presentation will b |
ZOM Price Returns
| 1-mo | -15.90% |
| 3-mo | -36.13% |
| 6-mo | -35.98% |
| 1-year | -73.08% |
| 3-year | -16.00% |
| 5-year | -88.08% |
| YTD | -31.48% |
| 2021 | 32.91% |
| 2020 | -30.33% |
| 2019 | -73.09% |
| 2018 | -37.88% |
| 2017 | 91.99% |
Loading social stream, please wait...